Omapatrilat was developed as a dual neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE) inhibitor that has been experimentally assessed as a hypertension treatment, while tenatoprazole was a clinical candidate for peptic ulcer and reflux functioning as a proton pump inhibitor. Here, ACE is linked to peptic ulcer disease.